Zimulti Loses On Weight Loss; Sanofi May Try Diabetes Route To Get Approval
Executive Summary
If FDA concurs with the Endocrinologic and Metabolic Drugs Advisory Committee's negative opinion of the pending obesity indication for Zimulti (rimonabant), Sanofi-Aventis may have another attempt at bringing the drug to market for type 2 diabetes